VIENNALAB - Established innovations in diagnostics

The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.

Efficiency of HCV therapy

  • Pegylated interferon/ribavirin (pegIFN/RBV) therapy is commonly used for treatment of HCV infection
  • SVR is dependent on virus genotype and also on patients’ factors including genetic polymorphisms
  • The rs368234815 TT>ΔG variant in the IFNL4 gene is the strongest known host factor for predicting HCV clearance
  • Genotyping of rs368234815 TT>ΔG helps to predict the outcome of pegIFN/RBV therapy independent of a patient’s ethnicity

Product Details

IL28B RealFast™ Assay ref7-200